- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acid sphingomyelinase deficiency (ASMD)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 910KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 503KB)
Olipudase alfa – July 2023
Olipudase alfa: Powder for I.V. infusion 20 mg; Xenpozyme® - July 2023
Last updated
10 November 2023